dystrophin protein

The FDA will speed up the review process for a promising exon-skipping drug designed to treat Duchenne MD caused by specific dystrophin mutations

posted on July 3, 2013 - 9:51am
Multinational pharmaceutical company GlaxoSmithKline (GSK) has announced that its experimental Duchenne muscular dystrophy (DMD) drug drisapersen has received breakthrough therapy designation from the U.S. Food and Drug Administration.

Researchers say the muscle-repair protein WNT7a may hold promise as a therapy for both Duchenne and Becker muscular dystrophies

posted on November 27, 2012 - 6:00am

Inflammation exacerbates muscle destruction in Duchenne muscular dystrophy, and several investigators — including some on the International Space Station — are trying to block it

posted on September 13, 2012 - 4:27pm
Inflammation — the immune system's first line of defense in tissue that's been damaged by injury or infection — is a good example of a process that's a good thing up to a point and under certain circumstances and a bad thing in excess or under the wrong circumstances.